STRIVEing to describe small vessel disease
- PMID: 37236209
- DOI: 10.1016/S1474-4422(23)00197-7
STRIVEing to describe small vessel disease
Conflict of interest statement
GBF has received honoraria for lectures, advisory board participation, and investigator-initiated sponsored studies from Roche, OM Pharma, Eisai, Biogen, Novo Nordisk, Diadem, GE HealthCare, Novartis, Life Molecular Imaging, Avid Radiopharmaceuticals, Fujifilm, Combinostics, Boehringer Ingelheim, and Danone. WvdF has received honoraria for lectures, advisory board participation, and investigator-initiated sponsored studies from Biogen, Danone, Eisai, WebMD Neurology (Medscape), Novo Nordisk, Springer Healthcare, Oxford Health Policy Forum CIC, Roche, and Eli Lilly. All funding is paid to her institution. This Comment is dedicated to Franz Fazekas, a pioneer and visionary in the domain of cerebral small vessel disease in older adults.
Comment on
-
Neuroimaging standards for research into small vessel disease-advances since 2013.Lancet Neurol. 2023 Jul;22(7):602-618. doi: 10.1016/S1474-4422(23)00131-X. Epub 2023 May 23. Lancet Neurol. 2023. PMID: 37236211 Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical